USPSTF 2021 — Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons
| Field | Value |
|---|---|
| Issuing body | U.S. Preventive Services Task Force |
| Year | 2021 |
| Publication | JAMA 2021;325(3):265-279 |
| DOI | 10.1001/jama.2020.25019 |
| PMID | 33464343 |
Recommendations
- Nonpregnant adults (A recommendation): clinicians should ask all adults about tobacco use, advise stopping, and provide behavioural interventions and FDA-approved pharmacotherapy.
- Pregnant persons (A recommendation): clinicians should ask about tobacco use, advise stopping, and provide behavioural interventions.
- Pharmacotherapy in pregnancy (I statement): evidence insufficient to assess balance of benefits and harms.
- E-cigarettes (I statement): evidence insufficient to assess benefits and harms for cessation in adults; clinicians should direct patients to interventions with proven effectiveness.
Interpretation
The USPSTF position is the reference US preventive-care statement. Its A-grade recommendations mean high certainty of substantial net benefit. The two I statements mark genuine evidence gaps — not "no benefit", but "not yet proven" — which is why this site keeps e-cigarettes in the Controversies section rather than in Methods.